skip to Main Content
Targeting The HIV-1 Nucleocapsid Protein To Fight Antiretroviral Drug Resistance

Dihydroxypyrimidine Scaffold to Target HIV‑1 Nucleocapsid Protein

IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new class of HIV-1 NC inhibitors. The HIV-1 nucleocapsid (NC) protein is a target of great interest because it is essential for viral replication. A bioisosteric catechol replacement approach led to identification the 5-dihydroxypyrimidine-6-carboxamide scaffold and subsequent hit validation efforts generated optimized analogs showing improved NC inhibition and antiviral activity as well as good ADME and PK properties.

Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance

Additional links for reference:

IRBM Grant funding
Cordis EU
Project website

Back To Top